Northern Ireland is now included in the UK Government’s temporary ban on the private sale and supply of puberty-suppressing hormones, known as “puberty blockers”.
In light of the findings of the independent Cass Review, and to close potential loopholes that could be exploited by not having a UK-wide legislative approach on this matter, Minister Nesbitt concluded that NI should align with GB.
The Cass Review found that there is not a reliable evidence-base upon which to make clinical decisions about the use of “puberty blockers” to treat gender dysphoria/incongruence, or for children and their families to make informed choices. The Cass Review concluded that because of the limited evidence, and potential risks to patient safety with regards neurocognitive development, psychosexual development and longer-term bone health, these medicines should only be offered for this purpose under a research protocol.
The safety of patients is paramount, and the Department will continue to work with DHSC and the other UK administrations to consider the development and implementation of permanent solutions.
Notes to editors:
- For media enquiries please contact the DoH Press Office by email pressoffice@health-ni.gov.uk.
- Follow us on X @healthdpt(external link opens in a new window / tab) and linkedIn Department of Health NI | LinkedIn(external link opens in a new window / tab)
- The Executive Information Service operates an out of hours service For Media Enquiries Only between 1800hrs and 0800hrs Monday to Friday and at weekends and public holidays. The duty press officer can be contacted on 028 9037 8110.
Latest news
- Patients encouraged to sign up for My Care portal 02 October 2024
- Our hospitals are better together - Nesbitt 01 October 2024
- Ministers launch Child Criminal Exploitation Action Plan 30 September 2024
- Nesbitt sets out series of autumn initiatives 30 September 2024